What is Strensiq?

Strensiq is an injectable drug precribed for the treatment of perinatal/infantile- and juvenile-onset hypophosphatasia. This rare and inherited metabolic disorder causes bone demineralization, rickets, and bone softening in children, along with complications like weakness, seizures, pain, and even death. Strensiq (asfotase alfa) replaces the enzyme missing in these patients and helps lead to normal bone development, improving survival rates in the first year dramatically. It is given as an injection three to six times a week. Side effects include sensitivity reactions (nausea, breathing problems, fever), injection site reactions (pain, redness/discoloration, itching, etc.), and calcium deposits in the kidneys or eyes. Patients are monitored closely for these adverse reactions.